Literature DB >> 25562667

eIF4E is an adverse prognostic marker of melanoma patient survival by increasing melanoma cell invasion.

Shahram Khosravi1, Kevin J Tam2, Gholamreza S Ardekani3, Magdalena Martinka4, Kevin J McElwee3, Christopher J Ong2.   

Abstract

Human cutaneous melanoma is a devastating skin cancer because of its invasive nature and high metastatic potential. We used tissue microarray to study the role of human eukaryotic translation initiation factor 4E (eIF4E) in melanoma progression in 448 melanocytic lesions and found that high eIF4E expression was significantly increased in primary melanomas compared with dysplastic nevi (P<0.001), and further increased in metastatic melanomas (P<0.001). High eIF4E expression was associated with melanoma thickness (P=0.046), and poor overall and disease-specific 5-year survival of all, and primary melanoma patients, especially those with tumors ≥1 mm thick. Multivariate Cox regression analysis revealed that eIF4E is an independent prognostic marker. eIF4E knockdown (KD) in melanoma cells resulted in a significant increase in apoptosis (sub-G1 populations) and decrease in cell proliferation, and also resulted in downregulation of mesenchymal markers and upregulation of E-cadherin. In addition, eIF4E KD led to a decrease in melanoma cell invasion, matrix metalloproteinase-2 expression and activity, c-myc and BCL2 expression, and an increase in cleaved PARP and cleaved caspase-3 expression and chemosensitivity. Taken together, our data suggest that the eIF4E may promote melanoma cell invasion and metastasis, and may also serve as a promising prognostic marker and a potential therapeutic target for melanoma.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25562667     DOI: 10.1038/jid.2014.552

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  49 in total

1.  Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5' cap.

Authors:  A Lazaris-Karatzas; K S Montine; N Sonenberg
Journal:  Nature       Date:  1990-06-07       Impact factor: 49.962

2.  EIF4E over-expresses and enhances cell proliferation and cell cycle progression in nasopharyngeal carcinoma.

Authors:  Mengyan Wu; Yingxia Liu; Xiaoqing Di; Haixian Kang; Hua Zeng; Yi Zhao; Kangrong Cai; Tianyun Pang; Sen Wang; Yunhong Yao; Xinrong Hu
Journal:  Med Oncol       Date:  2013-01-01       Impact factor: 3.064

Review 3.  Dual regulation of proliferation and apoptosis: c-myc in bitransgenic murine mammary tumor models.

Authors:  M H Jamerson; M D Johnson; R B Dickson
Journal:  Oncogene       Date:  2000-02-21       Impact factor: 9.867

4.  Inhibition of the p38 mitogen-activated protein kinase by SB 203580 blocks PMA-induced Mr 92,000 type IV collagenase secretion and in vitro invasion.

Authors:  C Simon; H Goepfert; D Boyd
Journal:  Cancer Res       Date:  1998-03-15       Impact factor: 12.701

5.  Skp2 overexpression increases the expression of MMP-2 and MMP-9 and invasion of lung cancer cells.

Authors:  Wen-Chun Hung; Wei-Lung Tseng; Jentaie Shiea; Hui-Chiu Chang
Journal:  Cancer Lett       Date:  2009-07-21       Impact factor: 8.679

6.  eIF4E activation is commonly elevated in advanced human prostate cancers and significantly related to reduced patient survival.

Authors:  Jeremy R Graff; Bruce W Konicek; Rebecca L Lynch; Chad A Dumstorf; Michele S Dowless; Ann M McNulty; Stephen H Parsons; Leslie H Brail; Bruce M Colligan; Jonathan W Koop; Bernadette M Hurst; James A Deddens; Blake L Neubauer; Louis F Stancato; Harry W Carter; Larry E Douglass; Julia H Carter
Journal:  Cancer Res       Date:  2009-04-21       Impact factor: 12.701

7.  Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity.

Authors:  Jeremy R Graff; Bruce W Konicek; Thomas M Vincent; Rebecca L Lynch; David Monteith; Spring N Weir; Phil Schwier; Andrew Capen; Robin L Goode; Michele S Dowless; Yuefeng Chen; Hong Zhang; Sean Sissons; Karen Cox; Ann M McNulty; Stephen H Parsons; Tao Wang; Lillian Sams; Sandaruwan Geeganage; Larry E Douglass; Blake Lee Neubauer; Nicholas M Dean; Kerry Blanchard; Jianyong Shou; Louis F Stancato; Julia H Carter; Eric G Marcusson
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

8.  Loss of SNF5 expression correlates with poor patient survival in melanoma.

Authors:  Hanyang Lin; Ronald P C Wong; Magdalena Martinka; Gang Li
Journal:  Clin Cancer Res       Date:  2009-10-06       Impact factor: 12.531

9.  Role of EIF5A2, a downstream target of Akt, in promoting melanoma cell invasion.

Authors:  S Khosravi; R P C Wong; G S Ardekani; G Zhang; M Martinka; C J Ong; G Li
Journal:  Br J Cancer       Date:  2013-10-31       Impact factor: 7.640

10.  Protein expression of eIF4E and integrin αvβ6 in colon cancer can predict clinical significance, reveal their correlation and imply possible mechanism of interaction.

Authors:  Zhengchuan Niu; Jiayong Wang; Shahbaz Muhammad; Weibo Niu; Enyu Liu; Cheng Peng; Benjia Liang; Qi Sun; Shinichi Obo; Zhaobin He; Song Liu; Xueqing Zou; Jun Niu
Journal:  Cell Biosci       Date:  2014-04-28       Impact factor: 7.133

View more
  14 in total

1.  Translation regulation in skin cancer from a tRNA point of view.

Authors:  Katerina Grafanaki; Dimitrios Anastasakis; George Kyriakopoulos; Ilias Skeparnias; Sophia Georgiou; Constantinos Stathopoulos
Journal:  Epigenomics       Date:  2018-12-19       Impact factor: 4.778

2.  Prognostic significance of eukaryotic initiation factor 4E in hepatocellular carcinoma.

Authors:  Xue-Mei Jiang; Xiang-Nan Yu; Ren-Zheng Huang; Hai-Rong Zhu; Xiao-Peng Chen; Ju Xiong; Zheng-Yi Chen; Xiao-Xi Huang; Xi-Zhong Shen; Ji-Min Zhu
Journal:  J Cancer Res Clin Oncol       Date:  2016-09-06       Impact factor: 4.553

3.  Differential Regulation of the Melanoma Proteome by eIF4A1 and eIF4E.

Authors:  Cailin E Joyce; Adrienne G Yanez; Akihiro Mori; Akinori Yoda; Johanna S Carroll; Carl D Novina
Journal:  Cancer Res       Date:  2016-11-22       Impact factor: 12.701

4.  MNK1/2 inhibition limits oncogenicity and metastasis of KIT-mutant melanoma.

Authors:  Yao Zhan; Jun Guo; William Yang; Christophe Goncalves; Tomasz Rzymski; Agnieszka Dreas; Eliza Żyłkiewicz; Maciej Mikulski; Krzysztof Brzózka; Aniela Golas; Yan Kong; Meng Ma; Fan Huang; Bonnie Huor; Qianyu Guo; Sabrina Daniela da Silva; Jose Torres; Yutian Cai; Ivan Topisirovic; Jie Su; Krikor Bijian; Moulay A Alaoui-Jamali; Sidong Huang; Fabrice Journe; Ghanem E Ghanem; Wilson H Miller; Sonia V Del Rincón
Journal:  J Clin Invest       Date:  2017-10-16       Impact factor: 14.808

Review 5.  Melanocytic nevi and melanoma: unraveling a complex relationship.

Authors:  W E Damsky; M Bosenberg
Journal:  Oncogene       Date:  2017-06-12       Impact factor: 9.867

6.  Proteomic identification of a marker signature for MAPKi resistance in melanoma.

Authors:  Verena Paulitschke; Ossia Eichhoff; Christopher Gerner; Philipp Paulitschke; Andrea Bileck; Thomas Mohr; Phil F Cheng; Alexander Leitner; Emmanuella Guenova; Ieva Saulite; Sandra N Freiberger; Anja Irmisch; Bernhard Knapp; Nina Zila; Theodora-Pagona Chatziisaak; Jürgen Stephan; Joanna Mangana; Rainer Kunstfeld; Hubert Pehamberger; Ruedi Aebersold; Reinhard Dummer; Mitchell P Levesque
Journal:  EMBO J       Date:  2019-06-26       Impact factor: 11.598

7.  Overexpression of eIF4E in colorectal cancer patients is associated with liver metastasis.

Authors:  Tao Xu; Yuanyuan Zong; Lipan Peng; Shuai Kong; Mingliang Zhou; Jianqiang Zou; Jinglei Liu; Ruizheng Miao; Xichao Sun; Leping Li
Journal:  Onco Targets Ther       Date:  2016-02-19       Impact factor: 4.147

8.  eIF4E promotes tumorigenesis and modulates chemosensitivity to cisplatin in esophageal squamous cell carcinoma.

Authors:  Ting Liu; Rong Li; Hui Zhao; Juan Deng; Ying Long; Meng-Ting Shuai; Qian Li; Huan Gu; Ya-Qi Chen; Ai-Min Leng
Journal:  Oncotarget       Date:  2016-10-11

9.  Expression analysis and clinical significance of eIF4E, VEGF-C, E-cadherin and MMP-2 in colorectal adenocarcinoma.

Authors:  Minna Gao; Xiong Zhang; Dan Li; Ping He; Wenguang Tian; Bo Zeng
Journal:  Oncotarget       Date:  2016-12-20

Review 10.  Beyond molecular tumor heterogeneity: protein synthesis takes control.

Authors:  Santiago Ramon Y Cajal; Josep Castellvi; Stefan Hümmer; Vicente Peg; Jerry Pelletier; Nahum Sonenberg
Journal:  Oncogene       Date:  2018-02-21       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.